This week saw some mixed news in coronavirus research as questions were raised about access to COVID-19 drugs as studies – and approvals – continued apace.
The use of artificial intelligence (AI) in drug development has been hyped up for some time now – and the COVID-19 pandemic is finally a chance for these technologies to prove their worth.
Research into drugs that could treat or prevent COVID-19 continued full steam ahead this week as the industry puts all its resources into fighting the coronavirus pandemic.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.